Table 3.
Predictive Values of ThyroSeq v2 for malignancy, by institution and combined, with NIFTP alternatively considered benign and malignant. MSKCC, Memorial Sloan-Kettering Cancer Center; MCC, Moffitt Cancer Center; CSMC, Cedars-Sinai Medical Center; MSHS, Mount Sinai Health System; PPV, positive predictive value; NPV, negative predictive value.
| Institution | ThyroSeq Status |
Malignant | NIFTP | Benign | Diagnostic Performance (NIFTP Benign) |
Diagnostic Performance (NIFTP Malignant) |
|---|---|---|---|---|---|---|
| MSKCC | ThyroSeq- positive (n=74) |
32 (43%) | 30 (41%) | 12 (16%) | PPV-43% NPV-88% Sensitivity-91% Specificity-33% |
PPV-84% NPV-79% Sensitivity-93% Specificity-61% |
| ThyroSeq- negative (n=24) |
3 (13%) | 2 (8%) | 19 (79%) | |||
| MCC | ThyroSeq- positive (n=33) |
11 (33%) | 5 (15%) | 17 (52%) | PPV-33% NPV-94% Sensitivity-73% Specificity-75% |
PPV-48% NPV-87% Sensitivity-64% Specificity-78% |
| ThyroSeq- negative (n=69) |
4 (6%) | 5 (7%) | 60 (87%) | |||
| CSMC | ThyroSeq- positive (n=11) |
3 (27%) | 1 (9%) | 7 (64%) | PPV- 27% NPV-100% Sensitivity-100% Specificity-20% |
PPV-36% NPV-100% Sensitivity-100% Specificity-22% |
| ThyroSeq- negative (n=2) |
0 (0%) | 0 (0%) | 2 (100%) | |||
| MSHS | ThyroSeq- positive (n=37) |
8 (22%) | 2 (5%) | 27 (73%) | PPV-22% NPV-96% Sensitivity-89% Specificity-43% |
PPV-27% NPV-91% Sensitivity-83% Specificity-44% |
| ThyroSeq- negative (n=23) |
1 (4%) | 1 (4%) | 21 (91%) | |||
| Overall |
ThyroSeq- positive (n=155) |
54 (35%) | 38 (25%) | 63 (41%) |
PPV-35% NPV-93% Sensitivity-87% Specificity-52% |
PPV-59% NPV-86% Sensitivity-85% Specificity-62% |
|
ThyroSeq- negative (n=118) |
8 (7%) | 8 (7%) | 102 (86%) |